Funakoshi, Takeru

写真a

Affiliation

School of Medicine, Department of Dermatology (Shinanomachi)

Position

Senior Assistant Professor (Non-tenured)/Assistant Professor (Non-tenured)

External Links

Profile 【 Display / hide

  • 電子顕微鏡による微細構造解析、皮膚病理学を研究テーマとしていた。その後、天疱瘡における自己抗体サブクラス解析を経て、皮膚がん領域の研究活動に従事するようになる。現在は、主に介入型の医師主導臨床試験の計画と実施を主たる研究テーマとし、日々の診療と並行して研究を遂行している。

Career 【 Display / hide

  • 2009.08
    -
    2010.07

    University of Pennsylvania, Department of Dermatology, Visiting Scholar

  • 2010.08
    -
    2014.09

    Keio University School of Medicine, Department of Dermatology, 助教

  • 2014.10
    -
    Present

    Keio University School of Medicine, Department of Dermatology, Assistant Professor

Academic Background 【 Display / hide

  • 1995.04
    -
    2001.03

    Keio University, School of Medicine

    Japan, University, Graduated

Academic Degrees 【 Display / hide

  • 博士(医学), Keio University, Dissertation

Matters concerning Career Achievements 【 Display / hide

  • 2015.06

    慶應義塾大学プレスリリース「創傷部にメラノーマ(ほくろのがん)が転移するしくみを解明 創傷が治癒する際に生じるペリオスチンが原因」

 

Research Areas 【 Display / hide

  • Dermatology

Research Keywords 【 Display / hide

  • Skin cancer

Research Themes 【 Display / hide

  • Clinical Trial on Skin Cancer, 

    2010.08
    -
    Present

 

Books 【 Display / hide

  • 皮膚科のくすりの使い方

    舩越建, じほう, 2019.08

    Scope: 悪性腫瘍(メラノーマ),  Contact page: 218-222

  • マイナー外科救急レジデントマニュアル

    Funakoshi Takeru, 医学書院, 2016.07

    Scope: 262-298

Papers 【 Display / hide

  • Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results

    Kamata A., Kurihara Y., Funakoshi T., Takahashi H., Kuroda K., Hachiya T., Amagai M., Yamagami J.

    British Journal of Dermatology (British Journal of Dermatology)  182 ( 5 ) 1221 - 1227 2020.05

    Joint Work, Accepted,  ISSN  00070963

     View Summary

    © 2019 British Association of Dermatologists Background: A subset of patients with bullous pemphigoid (BP) show deposition of IgE in the basement membrane zone (BMZ), yet the relationship between BMZ IgE and the clinical presentation of BP remains unclear. Objectives: To investigate the relationship between IgE deposition, IgE levels in serum, and disease severity in patients with BP. Methods: We investigated IgE autoantibodies in 53 patients with BP by direct immunofluorescence (DIF), indirect immunofluorescence and enzyme-linked immunosorbent assay. Results: Of 53 patients with BP, 23 (43%) had IgE deposition, 10 (19%) of whom were IgE+ and 13 (25%) IgE± according to DIF analyses. Erosion/blister (E/B) Bullous Pemphigoid Disease Area Index (BPDAI) scores were significantly higher in IgE+ patients than in IgE− patients (n = 15), while no significant differences were found for urticaria/erythema BPDAI scores. IgE+ and IgE± patients took longer to reduce their E/B BPDAI score by 75% after systemic corticosteroid treatment. BP180-IgE levels were significantly higher among IgE+ patients than IgE± or IgE− patients (n = 10). Total IgE levels in the serum and blood eosinophil counts did not differ between IgE+, IgE± and IgE− patients. A significant correlation was detected between BP180-IgG and BP180-IgE, but not between BPDAI scores and any of BP180-IgG, BP180-IgE or blood eosinophil count. Conclusions: IgE deposition in the BMZ is associated with higher E/B BPDAI scores and longer treatment periods. We conclude that IgE binding in the BMZ may contribute to BP pathogenesis by promoting blister formation. What's already known about this topic?. BP180-IgE autoantibodies have an important role in the pathogenesis of bullous pemphigoid (BP). A subset of patients with BP display deposition of IgE within the basement membrane zone (BMZ) of skin tissue. What does this study add?. Patients with in vivo IgE deposition in the BMZ displayed higher erosion/blister Bullous Pemphigoid Disease Area Index (BPDAI) scores, while urticaria/erythema BPDAI scores were not significantly different. Patients with in vivo IgE deposition in the BMZ took longer to reduce their erosion/blister BPDAI score by 75% after systemic corticosteroid treatment. BP180-specific IgE levels in serum were higher among patients with linear IgE deposition in the BMZ than in those with granular or no IgE deposition.

  • Metastatic Cutaneous Squamous Cell Carcinoma in Liver Successfully Treated With Partial Hepatectomy and Adjuvant Irinotecan Chemotherapy

    Asahina Y, Nakamura Y, Tanese K, Hirai I, Fukuda K, Amagai M, Funakoshi T

    In Vivo 34 ( 2 ) 825 - 828 2020.03

    Joint Work, Accepted,  ISSN  0258-851X

  • Case of metastatic cutaneous myoepithelial carcinoma lacking severe cytological atypia

    Hirai I, Tanese K, Nakamura Y, Amagai M, Mikami S, Funakoshi T

    J Dermatol 47 ( 3 ) e97 - e98 2020.03

    Joint Work, Accepted,  ISSN  0385-2407

  • Primary malignant melanoma of the uterine cervix or vagina which were successfully treated with nivolumab

    Anko M., Nakamura M., Kobayashi Y., Tsuji K., Nakada S., Nakamura Y., Funakoshi T., Banno K., Aoki D.

    Journal of Obstetrics and Gynaecology Research (Journal of Obstetrics and Gynaecology Research)  46 ( 1 ) 190 - 195 2020.01

    Joint Work, Accepted,  ISSN  13418076

     View Summary

    © 2019 Japan Society of Obstetrics and Gynecology Primary malignant melanomas (MM) originating from the gynecological tract are rare. They respond poorly to immunotherapy when compared with cutaneous MM. This study reports two cases. The first is of a 54-year-old woman with a cervical amelanotic polypoid mass who was diagnosed as having stage IB1 cervical melanoma according to the International Federation of Gynecology and Obstetrics system. At 17 months post-surgery, a computed tomography examination revealed recurrence of a 68 mm pelvic tumor. The second case is of a 37-year-old woman with a 7 cm hemorrhagic mass on the vaginal wall. The patient was diagnosed as having stage IV vaginal melanoma according to the American Joint Committee on Cancer definition. Both patients received nivolumab therapy, programmed cell death receptor 1 monoclonal antibodies, and the tumors almost disappeared. These cases may add the possibility of using colposcopy with narrow-band imaging and positron-emission tomography to diagnose and evaluate primary MM.

  • Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy

    Iga N., Otsuka A., Hirata M., Kataoka T., Irie H., Nakashima C., Matsushita S., Uchi H., Yamamoto Y., Funakoshi T., Fujisawa Y., Yoshino K., Fujimura T., Hata H., Ishida Y., Kabashima K.

    Cancer Science (Cancer Science)  110 ( 11 ) 3434 - 3441 2019.11

    Joint Work, Accepted,  ISSN  13479032

     View Summary

    © 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. Immune checkpoint inhibitors have improved the prognosis of advanced melanoma. Although anti–programmed death ligand-1 (PD-L1) is a well-studied biomarker for response to anti–programmed death-1 PD-1 therapy in melanoma, its clinical relevance remains unclear. It has been established that the high expression of indoleamine 2,3-dioxygenase (IDO) is correlated to a response to anti–CTLA-4 treatment in melanoma. However, it is still unknown whether the IDO expression is associated with response to anti–PD-1 therapy in advanced melanoma. In addition, acral and mucosal melanomas, which comprise a great proportion of all melanomas in Asians, are genetically different subtypes from cutaneous melanomas; however, they have not been independently analyzed due to their low frequency in Western countries. To evaluate the association of IDO and PD-L1 expression with response to anti–PD-1 antibody in acral and mucosal melanoma patients, we analyzed 32 Japanese patients with acral and mucosal melanomas treated with anti–PD-1 antibody from the perspective of IDO and PD-L1 expression levels by immunohistochemistry (IHC). Multivariate Cox regression models showed that the low expression of IDO in tumors was associated with poor progression-free survival (HR = 0.33, 95% CI = 0.13-0.81, P = 0.016), whereas PD-L1 expression on tumors was not associated with progression-free survival. Significantly lower expression of IDO in tumors was found in non–responders compared to responders. Assessment of the IDO expression could be useful for the identification of suitable candidates for anti–PD-1 therapy among acral and mucosal melanomas patients. Further validation study is needed to estimate the clinical utility of our findings.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • 乳房外パジェット病の病勢評価における血清CEAとCYFRA21-1のコンビネーションアッセイの有用性

    中村 善雄, 種瀬 啓士, 平井 郁子, 河上 裕, 天谷 雅行, 舩越 建

    日本皮膚科学会雑誌 ((公社)日本皮膚科学会)  129 ( 5 ) 1162 - 1162 2019.05

    ISSN  0021-499X

  • 天疱瘡の寛解後に水疱性類天疱瘡を発症した1例

    田原海, 古市祐樹, 新川宏樹, 齋藤昌孝, 久保亮治, 天谷雅行, 舩越建, 山上淳

    第883回日本皮膚科学会東京地方会(城西地区) ((公社)日本皮膚科学会)  129 ( 6 ) 1348 - 1348 2019.05

    ISSN  0021-499X

  • 全身性エリテマトーデスへ高用量ステロイド投与中に血管炎を生じた1例 IgA血管炎との合併か?

    朝比奈 泰彦, 田中 諒, 新川 宏樹, 舩越 建, 山田 裕揮, 太田 裕一朗, 仁科 直, 竹内 勤, 谷川 瑛子

    日本皮膚科学会雑誌 ((公社)日本皮膚科学会)  129 ( 5 ) 1182 - 1182 2019.05

    ISSN  0021-499X

  • 遠隔転移をきたした悪性皮膚混合腫瘍の1例

    平井 郁子, 中村 善雄, 種瀬 啓士, 天谷 雅行, 三上 修治, 舩越 建

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集 ((一社)日本皮膚悪性腫瘍学会)  35回   159 - 159 2019.04

  • β-catenin染色によって平滑筋肉腫と鑑別し経過観察の方針としたextra abdominal fibromatosisの1例

    入來景悟, 知念克也, 鈴木友博, 大内健嗣, 舩越建, 三上修治, 亀山香織, 横内麻里子

    第82回日本皮膚科学会東京支部学術大会 ((公社)日本皮膚科学会)  129 ( 4 ) 599 - 599 2019.04

    ISSN  0021-499X

display all >>

Presentations 【 Display / hide

  • 造影CTで活動性出血の所見なく、血腫除去時に判明したdeep dissecting hemtomaの1例

    小川夕貴, 伏間江貴之, 舩越建, 加藤達也, 岡部圭介, 小林秀, 天谷雅行, 山上淳

    第889回日本皮膚科学会東京地方会(城西地区) (東京) , 2020.02

  • 薬疹 経過中に自己抗体が出現した薬剤性過敏症症候群および疑い例の検討

    椎谷千尋, 大内健嗣, 舩越建, 天谷雅行, 高橋勇人

    第49回日本皮膚免疫アレルギー学会総会学術大会 (横浜) , 2019.11

  • 激しい腹痛と肝機能障害を伴い重症化した内臓播種性水痘ウィルス感染症の1例

    野澤優, 朝倉涼平, 山上淳, 天谷雅行, 舩越建

    第886回日本皮膚科学会東京地方会(城西地区) (東京) , 2019.10

  • 免疫チェックポイント阻害薬治療中に発症したが、投与を継続した水疱性類天疱瘡の1例

    新谷悠花, 齋藤京, 長谷衣佐乃, 舩越建

    第886回日本皮膚科学会東京地方会(城西地区) (東京) , 2019.10

  • 陰圧閉鎖療法が分層植皮固定に有用であった外陰部乳房外Paget病(EMPD)の1例

    及川紗由香, 新川宏樹, 平井郁子, 中村善雄, 大内健嗣, 舩越建

    第886回日本皮膚科学会東京地方会(城西地区) (東京) , 2019.10

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • [再生医療実用化研究事業] 進行性の悪性黒色腫および子宮頸癌に対する腫瘍浸潤Tリンパ球輸注療法

    2018.04
    -
    2021.03

    国立研究開発法人日本医療研究開発機構, 再生医療実用化研究事業, Yutaka Kawakami, Co-investigator

  • [難治性疾患等実用化研究事業 難治性疾患実用化研究事業] ステロイド治療抵抗性の天疱瘡患者を対象としたリツキシマブの医師主導治験

    2017.04
    -
    2020.03

    国立研究開発法人日本医療研究開発機構, 日本医療研究開発機構研究費, Masayuki Amagai, Co-investigator

  • [臨床研究・治験推進研究事業] 進行期乳房外パジェット病に対するトラスツズマブ、ドセタキセル併用療法の第II相臨床試験

    2017.04
    -
    2020.03

    国立研究開発法人日本医療研究開発機構, 臨床研究・治験推進研究事業, Principal Investigator

  • [革新的がん医療実用化研究事業] 進行期悪性黒色腫(末端黒子型)に対する非骨髄破壊性前処置併用での腫瘍浸潤Tリンパ球輸注療法の安全性試験

    2015
    -
    2017

    AMED(国立研究開発法人日本医療研究開発機構), 河上 裕

  • [「健康長寿の世界標準を創出するシステム医学・医療拠点」研究助成] マルチスペクトルカメラを用いた皮膚病変のコンピュータ診断補助システムの開発

    2014.04
    -
    2015.03

    科学技術振興機構(JST) COIプログラム, 舩越建

display all >>

Works 【 Display / hide

  • 日経産業新聞「免疫細胞、体外培養し投与、慶大が臨床試験、メラノーマ対象。」

    舩越建

    2016.09

    Other

  • 日経産業新聞「メラノーマの転移 解明」

    福田桂太郎, 舩越建, 天谷雅行

    2015.06

    Other

  • 週刊エコノミスト「+健康アプリ:72皮膚がん」

    舩越建

    2014.02

    Other

 

Courses Taught 【 Display / hide

  • PATHOPHYSIOLOGY AND CLINICAL ASSESSMENT

    2020

  • PATHOPHYSIOLOGICAL ISSUES IN CHRONIC CARE

    2020

  • LECTURE SERIES, DERMATOLOGY

    2020

  • PATHOPHYSIOLOGY AND CLINICAL ASSESSMENT

    2019

  • PATHOPHYSIOLOGICAL ISSUES IN CHRONIC CARE

    2019

display all >>

Courses Previously Taught 【 Display / hide

  • 皮膚科学

    学校法人慶應義塾大学, 2018

  • Dermatology

    Keio University, 2017

  • 皮膚科学講義「真皮、皮下脂肪組織の疾患」「代謝異常症」2016/11/24

    Keio University, 2016

  • 皮膚科学講義「真皮、皮下脂肪組織の疾患」「代謝異常症」2015/11/19     

    Keio University, 2015

  • 皮膚科学講義「真皮、皮下脂肪組織の疾患」2013/11/25

    Keio University, 2013

display all >>

 

Memberships in Academic Societies 【 Display / hide

  • Japanese Dermatological Association, 

    2001
    -
    Present

Committee Experiences 【 Display / hide

  • 2017.04
    -
    Present

    乳房外パジェット病ガイドライン作成委員, 乳房外パジェット病ガイドライン作成委員会